Belgium· BE-AMP-SAM666462-00
Jascayd 9 mg
A nerandomilast product containing nerandomilast, registered in Belgium by Boehringer Ingelheim International. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nerandomilast is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA61 (nerandomilast), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Nerandomilast · ATC L04AA61
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nerandomilast
- Manufacturer
- Boehringer Ingelheim International
- Country
- Belgium (BE)
- ATC code
- L04AA61
- ATC class
- Nerandomilast
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nerandomilast in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJASCAYDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United StatesJASCAYDBoehringer Ingelheim Pharmaceuticals, Inc.
- FinlandJascaydBoehringer Ingelheim International GmbH
- IrelandJascayd 9 mg film-coated tabletsBoehringer Ingelheim International GmbH
- NetherlandsJascayd 9 mg filmomhulde tablettenBoehringer Ingelheim International GmbH
- PolandJascaydBoehringer Ingelheim International GmbH
- SwedenJascayd 9 mg Filmdragerad tablettBoehringer Ingelheim International GmbH
- SpainJASCAYD 9 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jascayd
- Liechtenstein · Jascayd
- Norway · Jascayd
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2b85781b-4eff-47e5-a65c-106232d248f4 GET /v1/drugs/2b85781b-4eff-47e5-a65c-106232d248f4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Jascayd 9 mg",
"name_fr": "Jascayd 9 mg",
"name_nl": "Jascayd 9 mg",
"amp_code": "SAM666462-00",
"strengths": [
"9.0000",
"81.8000"
],
"pack_count": 5,
"substances": [
"Nerandomilast",
"Lactose",
"Mannitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nerandomilast",
"authorisation_numbers": [
"EU/1/26/2040/001",
"EU/1/26/2040/004",
"EU/1/26/2040/005",
"EU/1/26/2040/003",
"EU/1/26/2040/002"
]
}See everything about nerandomilast.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.